Peptide blends and stacks

What a blend is

Each product on this page is a single vial of freeze-dried powder that holds two to four peptides. Their names use both words, as in KLOW Peptide Blend and Glow Peptide Stack. "Stack" also describes peptides used together outside one vial.

Approved medicines face a specific test before two drugs can share one dose form. Under FDA's rule for fixed-combination prescription drugs, each component must contribute to the claimed effects, and the dose of each must make the combination safe and effective for a significant patient population.¹⁴ None of these blends has been through that review. Each contains at least one peptide that is not a component of any FDA-approved drug: BPC-157 and TB-500 in the first three, CJC-1295 and ipamorelin in the fourth.^8151617

What is in each blend

BPC-157 and TB-500 are in three of the four vials. Glow and KLOW share three peptides, and KLOW adds KPV. CJC-1295 + Ipamorelin is the only one built around growth hormone release: both of its peptides act on receptors in the pituitary gland.¹⁶²⁰

What research covers each combination

KLOW: four peptides, no combination data

No published study has tested KLOW or the trio of BPC-157, KPV and GHK-Cu: a PubMed search for those three together returned no records, and a ClinicalTrials.gov search for KLOW returned one unrelated study (October 2026).¹¹⁸ KPV, the peptide KLOW adds to Glow's three, has been studied in animals but not in people: it showed anti-inflammatory effects in two mouse models of colitis,²¹ and FDA found no clinical studies or human exposure data for it by any route.⁶ Read the KLOW profile or see KLOW Peptide Blend for sale; the single-peptide profiles are KPV and GHK-Cu.

Glow: mostly GHK-Cu by weight

GHK-Cu makes up 50 of Glow's 60 mg, and most human studies of GHK-Cu used creams or gels on the skin.²²²³ In a randomized, placebo-controlled trial in people with diabetic foot ulcers, a GHK-Cu gel raised median ulcer closure to 98.5%, against 60.8% with the plain gel (1994).²³ A 2026 review says controlled human trials of injected GHK-Cu are absent,⁷ and FDA says injectable GHK-Cu may pose a risk of immune reactions, with limited human data.²⁴ The same review warns that excessive systemic delivery of copper-binding peptides can disturb the body's copper balance, leading to oxidative stress and possible liver toxicity.⁷ Read the Glow profile or see Glow Peptide Stack for sale.

Wolverine Stack: one rat study of the pair

In a 2026 study, 32 male rats with surgically repaired Achilles tendons got BPC-157, TB-500, both, or no treatment by injection into the abdominal cavity for 4 weeks. The combination gave no added benefit over either peptide alone, and only TB-500 alone significantly raised the tendon's load to failure.⁵ The rats received the two peptides at a 1 to 6 ratio by weight, not the 1 to 1 ratio in this vial.⁵ In people, the pair appears only in uncontrolled reports.¹⁰¹¹ Read the Wolverine Stack profile or see Wolverine Stack (BPC-157 + TB-500) for sale, with single-peptide profiles for BPC-157 and TB-500.

CJC-1295 + Ipamorelin: two routes to growth hormone

CJC-1295 without DAC copies the active 29-amino-acid stretch of GHRH, the hormone that signals the pituitary to release growth hormone, with four amino acids swapped.¹⁶ Ipamorelin acts on a separate pituitary receptor, the ghrelin receptor (GHSR-1a).²⁰ Synergy between these two pathways has been shown with other peptides: in a 1990 study of 18 healthy men, low doses of GHRP-6 plus GHRH released growth hormone synergistically.⁹ For CJC-1295 with ipamorelin, a 2026 review says the pairing rests largely on anecdotal rationale and that controlled clinical evidence of synergy remains limited.²⁰ Another 2026 review reports that the pair improved muscle force in mice with glucocorticoid-induced muscle loss, an animal finding only.²⁵ FDA found no human study of CJC-1295 without DAC,¹⁶ and for ipamorelin it found human data only for the intravenous route, none for injection under the skin.¹⁷ Read the CJC-1295 + Ipamorelin profile or see CJC-1295 + Ipamorelin for sale, along with the profiles of CJC-1295 without DAC, the long-acting CJC-1295 with DAC and ipamorelin.

Questions every blend raises

Which peptide caused a reaction?

A mix makes side effects harder to trace. FDA's adverse event database holds a report of a 40-year-old woman who injected a research-labeled product containing BPC-157 and TB-500 under the skin and developed darkening of the skin and gums, which returned when she restarted it.⁸ FDA judged the reaction likely due to the product, but said it could not assess BPC-157's role because the product contained two peptides.⁸

Is a dose established?

No human dose is established for KLOW, Glow or the Wolverine Stack, or for any of their peptides given by injection; a 2026 review says the indications, dosing, frequency and duration of treatment for these injectable peptides remain unknown.²⁵ No dose of CJC-1295 without DAC, ipamorelin or the pair is established for people either.¹⁶¹⁷

Do the peptides stay stable together?

FDA notes that peptides can be extremely sensitive to pH, heat, concentration and impurities, which may lead to clumping (aggregation) and breakdown.⁸¹⁵ The storage and solubility figures in FDA's reviews describe each peptide alone, not mixtures.⁸¹⁵ The components also differ: BPC-157 free base dissolves in water at 5 mg/mL and TB-500 free base at 50 mg/mL,⁸¹⁵ while CJC-1295 without DAC, as the free base, is only slightly soluble in water.¹⁶

What do the vial amounts mean once mixed?

When a blend is reconstituted, any concentration refers to the total peptide in the vial, split by the blend's ratio. A 10 mg vial holding 5 mg of each of two peptides, mixed with 2 mL of diluent, holds 5 mg/mL in total, or 2.5 mg/mL of each. In Glow, GHK-Cu is five-sixths of the peptide mass and BPC-157 and TB-500 are one-twelfth each, at any volume. KLOW's split cannot be calculated, because only its 70 mg total is disclosed. The peptide calculator and the guide to reconstituting a vial cover the arithmetic.

How has FDA treated other blends?

In August 2026 warning letters, FDA named two blends sold by online peptide sellers as unapproved new drugs: a "Tesamorelin Ipamorelin Blend" and "BIMORELIN," described by its seller as tesamorelin 10 mg plus ipamorelin 3 mg.²⁶²⁷ The research peptides page explains how FDA judges a research-labeled product.

Where to read next

The goal pages place these blends among other compounds: healing and recovery, skin and hair and muscle. Every other compound has a profile in Peptides A to Z.